CN116802199A - 靶向线粒体蛋白的工程化去泛素化酶及其使用方法 - Google Patents

靶向线粒体蛋白的工程化去泛素化酶及其使用方法 Download PDF

Info

Publication number
CN116802199A
CN116802199A CN202180089240.1A CN202180089240A CN116802199A CN 116802199 A CN116802199 A CN 116802199A CN 202180089240 A CN202180089240 A CN 202180089240A CN 116802199 A CN116802199 A CN 116802199A
Authority
CN
China
Prior art keywords
seq
fusion protein
deubiquitinase
sequence
hybridizes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180089240.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·罗伊
S·W·豪尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flax Therapy Co ltd
Original Assignee
Flax Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flax Therapy Co ltd filed Critical Flax Therapy Co ltd
Publication of CN116802199A publication Critical patent/CN116802199A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/19—Omega peptidases (3.4.19)
    • C12Y304/19012—Ubiquitinyl hydrolase 1 (3.4.19.12)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/07—Fusion polypeptide containing a localisation/targetting motif containing a mitochondrial localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180089240.1A 2020-11-06 2021-11-05 靶向线粒体蛋白的工程化去泛素化酶及其使用方法 Pending CN116802199A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110625P 2020-11-06 2020-11-06
US63/110,625 2020-11-06
PCT/US2021/058286 WO2022099034A2 (en) 2020-11-06 2021-11-05 Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof

Publications (1)

Publication Number Publication Date
CN116802199A true CN116802199A (zh) 2023-09-22

Family

ID=81458643

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180089240.1A Pending CN116802199A (zh) 2020-11-06 2021-11-05 靶向线粒体蛋白的工程化去泛素化酶及其使用方法

Country Status (7)

Country Link
US (1) US20240026330A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240753A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023549167A (cg-RX-API-DMAC7.html)
CN (1) CN116802199A (cg-RX-API-DMAC7.html)
AU (1) AU2021376278A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200982A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022099034A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115998769B (zh) * 2022-11-02 2025-12-09 中国人民解放军军事科学院军事医学研究院 以Mysm1基因为抑制靶标的物质在提高线粒体活性中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012177549A (ja) * 2009-06-24 2012-09-13 Hokkaido Univ 蛍光温度プローブおよびそれを用いた温度測定装置
EP2992892A1 (en) * 2014-09-05 2016-03-09 Universität zu Köln Fusion protein for use in the treatment of mitochondrial diseases
EP3706782A4 (en) * 2017-11-06 2021-09-08 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS OF USING MANIPULATED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELL PROCESSES
WO2019126762A2 (en) * 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12a systems, methods, and compositions for targeted rna base editing
AU2020224327B2 (en) * 2019-02-21 2022-09-29 Entact Bio Limited Survival-targeting chimeric ( SURTAC) molecules

Also Published As

Publication number Publication date
JP2023549167A (ja) 2023-11-22
CA3200982A1 (en) 2022-05-12
US20240026330A1 (en) 2024-01-25
WO2022099034A2 (en) 2022-05-12
AU2021376278A9 (en) 2025-03-27
EP4240753A4 (en) 2024-08-28
EP4240753A2 (en) 2023-09-13
WO2022099034A3 (en) 2022-06-09
AU2021376278A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
WO2007044756A2 (en) Monoclonal antibodies recognizing human ccr8
US12168696B2 (en) Antibodies to mucin-16 (MUC16), encoding polynucleotides and methods of treating MUC16-positive cancer
CN110724691A (zh) 补体因子Bb抗体
WO2015120138A2 (en) AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
US20250179210A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
CN119020330A (zh) 使用工程化的去泛素化酶探测泛素依赖性细胞过程的组合物和方法
US20240026329A1 (en) Nuclear protein targeting deubiquitinases and methods of use
US20240002473A1 (en) Membrane protein targeting engineered deubiquitinases and methods of use thereof
CN117729938A (zh) 用于使用利用抗muc16×cd3多特异性抗体和vegf抑制剂的组合疗法治疗妇科癌症的方法
US20240026330A1 (en) Mitochondrial protein targeting engineered deubiquitinases and methods of use thereof
US20240025984A1 (en) Cytosolic protein targeting deubiquitinases and methods of use
Doiron Rational Design of Selective Protein Therapeutics for Structurally and Functionally Complex Targets
CN121532429A (zh) Mhc i类链相关蛋白a (mica)特异性抗体及其用途
HK40049093B (en) Antibodies to mucin-16 and methods of use thereof
HK40049093A (en) Antibodies to mucin-16 and methods of use thereof
KR20240091042A (ko) 분리된 항원 결합 단백질 및 이의 용도
HK40021720A (en) Complement factor bb antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination